Vigil Neuroscience (NASDAQ:VIGL) Issues Quarterly Earnings Results

Vigil Neuroscience (NASDAQ:VIGL) issued its quarterly earnings results on Thursday. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08), Zacks reports.

Vigil Neuroscience Trading Down 8.6 %

NASDAQ VIGL traded down $0.20 during trading hours on Thursday, hitting $2.15. 27,793 shares of the company’s stock were exchanged, compared to its average volume of 466,949. The firm has a market cap of $87.85 million, a price-to-earnings ratio of -1.03 and a beta of 1.82. The stock has a 50-day simple moving average of $2.33 and a 200 day simple moving average of $2.81. Vigil Neuroscience has a 1-year low of $1.49 and a 1-year high of $6.06.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $17.00 price target on shares of Vigil Neuroscience in a report on Thursday, January 23rd. Guggenheim reissued a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. William Blair began coverage on Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an “outperform” rating on the stock. Finally, JMP Securities reiterated a “market outperform” rating and issued a $22.00 target price on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $19.75.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.